This post was originally published on this site.
Sedivention,
a Germany-based medtech startup, has raised €2.9 million in a seed funding
round led by bmp Ventures alongside the IBG funds. Additional investors include
the strategic investment arm of a global medtech company, High-Tech
Gründerfonds (HTGF), superangels, and Cambridge Ventures.
The
company is developing a minimally invasive, one-time outpatient therapy for the
treatment of obesity, a condition expected to affect more than one billion
people globally in the coming years. Existing treatment options, including
bariatric surgery and drug therapies, remain limited due to their invasiveness,
cost, or long-term dependency.
Sedivention’s
approach is based on a targeted cryo procedure delivered via a specially
designed balloon catheter, similar to a gastroscopy. The therapy uses precise
cryoablation to interrupt hunger-related signals in the vagus nerve, aiming to
address the underlying physiological mechanisms of obesity and enable sustained
appetite reduction without surgery, implants, or ongoing medication.
Dr Ute Nollert, founder and Chief Medical Officer of Sedivention, said that obesity is
a chronic disease requiring treatments that are both clinically effective and
minimally invasive:
Our
approach targets the underlying disruption in hunger and satiety regulation,
enabling a lasting reduction in hunger without invasive procedures or lifelong
treatment.
A
functional prototype has already been developed and tested. With the new
funding, Sedivention plans to advance product development, generate initial
clinical data through a first-in-human study, and prepare for subsequent
regulatory and market entry steps.
In the
long term, Sedivention aims to replace highly invasive surgical procedures with
outpatient interventional treatments, improving access to effective care.